Caribou Biosciences, Inc. Common Stock (CRBU) Stock
Key stats
- Market cap
- $42.21M
- Price / Earnings ratio
- -0.4x
- EPS (TTM)
- -$1.03
- Volume
- Loading
- 52-week high
- $2.49
- 52-week low
- $0.39
Source: third-party data provider, as of November 13, 2026
Compare with CRBU
Recent news

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CRBU

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
CRBU

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
CRBU

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
CRBU
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 27.38
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.15
- MACD histogram
- 0.02
- SMA 50
- $0.88
- Price below SMA 50
- EMA 50
- $0.81
- Price below EMA 50
- SMA 200
- $1.59
- Price below SMA 200
- EMA 200
- $1.41
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CRBU

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
CRBU

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
CRBU

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
CRBU

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
CRBU

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
CRBU

Three Best Genomics Stocks for Your Portfolio in 2026
Three Best Genomics Stocks for Your Portfolio in 2026
CRBU

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates
CRBU

Genomics Stocks That Deserve a Place in Your Portfolio in 2026
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
CRBU

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
CRBU
News tone: automated (AI) classification of the article's content, not a price prediction.
About Caribou Biosciences, Inc. Common Stock
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, President & Director | 1986 |
| Mr. Sriram Ryali M.B.A. | Chief Financial Officer | 1982 |
| Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1955 |
| Dr. Jennifer A. Doudna Ph.D. | Co-founder & Member of Scientific Advisory Board | 1964 |
| Mr. Ryan Fischesser | Interim Principal Accounting Officer & Controller | — |
| Ms. Reigin Zawadzki | Chief People Officer | — |
| Dr. Tina Albertson M.D., Ph.D. | Chief Medical Officer | 1974 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 27.38
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.15
- MACD histogram
- 0.02
- SMA 50
- $0.88
- Price below SMA 50
- EMA 50
- $0.81
- Price below EMA 50
- SMA 200
- $1.59
- Price below SMA 200
- EMA 200
- $1.41
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $1.00
- Average
- $2.33
- High
- $5.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.0 | +3.3 | -5.5 | +26.2 | -27.6 | -17.0 | +2.7 | -18.1 | -65.6 | -11.4 |



